[{"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-001", "question": "A 43-year-old woman undergoes bilateral DIEP free flap breast reconstruction after nipple-sparing mastectomy. Intraoperatively, the right flap requires an 11-cm venous graft to reach the internal mammary vein, and flow is satisfactory at closure. On postoperative day 3, she develops progressive swelling and violaceous discoloration of the right flap with brisk bleeding on pinprick and Dopplerable arterial signal in the pedicle but no venous signal. Exploration shows a patent arterial anastomosis, a soft flap, and a congested, thrombotic venous graft with limited nearby recipient veins. The contralateral internal mammary and thoracodorsal systems are already occupied by the left flap. Which salvage strategy offers the highest likelihood of durable flap survival?", "options": ["Shortening the flap pedicle with reanastomosis directly to the internal mammary vein after partial flap debulking to reduce reach and venous load", "Use of a retrograde internal mammary vein anastomosis via a newly dissected contralateral internal mammary perforator and interposition venous graft", "Creation of a venous cross-over (cross-chest) anastomosis from the congested flap vein to a contralateral DIEP flap superficial inferior epigastric vein branch", "Conversion of the free flap to a pedicled bipedicled transverse rectus abdominis myocutaneous (TRAM) flap by re-establishing inferior epigastric inflow and rotating the flap on its native pedicle", "Immediate complete flap removal and delayed reconstruction with a latissimus dorsi flap and implant after chemotherapy and radiation are completed"], "answer": "C", "answer_index": 2, "explanation": "Venous cross-over using a contralateral flap vein (often SIEV) is a recognized, high-yield salvage when ipsilateral recipient veins are exhausted, preserving a viable free flap. Shortening the pedicle (A) is not feasible given the reach problem and does not address lack of recipient vein; retrograde IMV with another vein graft (B) adds another long, failure-prone segment. Converting to pedicled TRAM (D) is not realistic once the flap is fully disconnected. Immediate flap loss (E) is last resort and avoids a proven microvascular salvage option.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes venous congestion of a DIEP flap on POD 3 with patent arterial inflow, thrombosed venous graft, and exhausted ipsilateral recipient veins (contralateral vessels occupied by left flap). Key discriminating findings: brisk capillary bleeding, violaceous discoloration, no venous Doppler signal, thrombotic venous graft, limited nearby recipient veins, contralateral vessels unavailable. The clinical problem is salvaging a viable but venous-congested free flap when standard ipsilateral recipient options are exhausted. Option C (venous cross-over to contralateral flap SIEV) is the keyed answer and represents established microsurgical salvage technique when ipsilateral recipients are unavailable—uses a proven, short-distance anastomosis to a reliable recipient vessel. Option A fails because shortening cannot overcome the stated reach problem and no recipient vein exists. Option B adds another long interposition graft with high thrombosis risk. Option D (conversion to pedicled TRAM) is anatomically impossible once the flap is fully divided and harvested as free tissue. Option E (flap removal) abandons a salvageable flap. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high—cross-chest venous salvage is well-documented in plastic surgery literature. Minimal fix: none needed; item is sound.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes venous congestion of a DIEP flap on POD 3 with patent arterial inflow, thrombosed venous graft, and exhausted ipsilateral recipient veins (contralateral vessels occupied by left flap). Key discriminating findings: brisk capillary bleeding, violaceous discoloration, no venous Doppler signal, thrombotic venous graft, limited nearby recipient veins, contralateral vessels unavailable. The clinical problem is salvaging a viable but venous-congested free flap when standard ipsilateral recipient options are exhausted. Option C (venous cross-over to contralateral flap SIEV) is the keyed answer and represents established microsurgical salvage technique when ipsilateral recipients are unavailable—uses a proven, short-distance anastomosis to a reliable recipient vessel. Option A fails because shortening cannot overcome the stated reach problem and no recipient vein exists. Option B adds another long interposition graft with high thrombosis risk. Option D (conversion to pedicled TRAM) is anatomically impossible once the flap is fully divided and harvested as free tissue. Option E (flap removal) abandons a salvageable flap. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high—cross-chest venous salvage is well-documented in plastic surgery literature. Minimal fix: none needed; item is sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-002", "question": "A 56-year-old man presents with progressive gait ataxia, urinary urgency, and cognitive slowing over 10 months. MRI shows ventriculomegaly out of proportion to mild cortical atrophy, but in addition there is a subtle nodular T1-hypointense, T2-hyperintense lesion in the posterior third ventricle near the aqueduct, with minimal enhancement and no diffusion restriction. Cine phase-contrast MRI demonstrates preserved CSF stroke volume at the cerebral aqueduct. A high-volume lumbar tap test produces only transient, equivocal improvement. Which is the most appropriate next neurosurgical management?", "options": ["Programmable ventriculoperitoneal shunt placement without further workup, given classic normal-pressure hydrocephalus symptoms", "Endoscopic third ventriculostomy with concurrent biopsy of the third ventricular lesion", "Endoscopic biopsy and possible debulking of the third ventricular lesion without CSF diversion, followed by observation", "Stereotactic radiosurgery targeted to the third ventricular lesion followed by reassessment of hydrocephalus", "External lumbar drainage trial over 72 hours before deciding on shunt placement"], "answer": "B", "answer_index": 1, "explanation": "The combination of ventriculomegaly and a small obstructive-appearing lesion near the aqueduct suggests a secondary obstructive hydrocephalus rather than idiopathic NPH; ETV addresses obstruction and allows tissue diagnosis for a possible low-grade tumor or colloid-like lesion. Shunting alone (A, E) ignores a likely focal obstructive cause and risks shunt dependence. Biopsy alone (C) does not treat hydrocephalus. SRS (D) is premature without histology and does not immediately relieve CSF obstruction.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes a 56-year-old with progressive gait ataxia, urinary urgency, and cognitive slowing—classic NPH triad—but crucially adds ventriculomegaly with a T1-hypointense, T2-hyperintense nodular lesion near the aqueduct in the posterior third ventricle. Key discriminating findings: (1) lesion location at aqueduct suggests obstructive pathology, (2) preserved CSF stroke volume on cine MRI argues against simple communicating NPH, (3) equivocal tap-test response undermines idiopathic NPH diagnosis. The clinical problem is determining whether this represents secondary obstructive hydrocephalus from a focal lesion (colloid cyst, low-grade tumor) versus idiopathic NPH. Option B (ETV with concurrent biopsy) addresses both the potential obstruction and provides tissue diagnosis in one procedure—standard neurosurgical approach when an obstructive lesion is suspected. Option A ignores the lesion and risks shunt-dependence for a potentially curable obstructive cause. Option C biopsies but leaves hydrocephalus untreated. Option D uses radiosurgery without histology—inappropriate without tissue diagnosis. Option E (extended lumbar drainage) is reasonable for equivocal NPH but doesn't address the structural lesion. The keyed answer is medically sound and logically unique given the obstructive lesion near the aqueduct. No contradictions, underspecification, or alternative equally defensible answers exist. Minimal fix: none needed; item is valid as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 56-year-old with progressive gait ataxia, urinary urgency, and cognitive slowing—classic NPH triad—but crucially adds ventriculomegaly with a T1-hypointense, T2-hyperintense nodular lesion near the aqueduct in the posterior third ventricle. Key discriminating findings: (1) lesion location at aqueduct suggests obstructive pathology, (2) preserved CSF stroke volume on cine MRI argues against simple communicating NPH, (3) equivocal tap-test response undermines idiopathic NPH diagnosis. The clinical problem is determining whether this represents secondary obstructive hydrocephalus from a focal lesion (colloid cyst, low-grade tumor) versus idiopathic NPH. Option B (ETV with concurrent biopsy) addresses both the potential obstruction and provides tissue diagnosis in one procedure—standard neurosurgical approach when an obstructive lesion is suspected. Option A ignores the lesion and risks shunt-dependence for a potentially curable obstructive cause. Option C biopsies but leaves hydrocephalus untreated. Option D uses radiosurgery without histology—inappropriate without tissue diagnosis. Option E (extended lumbar drainage) is reasonable for equivocal NPH but doesn't address the structural lesion. The keyed answer is medically sound and logically unique given the obstructive lesion near the aqueduct. No contradictions, underspecification, or alternative equally defensible answers exist. Minimal fix: none needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-003", "question": "A 68-year-old man with cT3N1M0 distal esophageal adenocarcinoma receives neoadjuvant chemoradiation with carboplatin/paclitaxel and 50.4 Gy in 28 fractions using IMRT. He has severe baseline interstitial lung disease (UIP pattern) with DLCO 35% predicted. At multidisciplinary review before simulation, the radiation oncologist must choose a planning goal that most reduces the risk of fatal radiation pneumonitis while still allowing adequate target coverage. Which constraint is most critical to prioritize in this scenario?", "options": ["Mean lung dose (MLD) <10 Gy, even if heart V40 increases modestly", "Total lung V20 <20%, accepting an MLD up to 15 Gy", "Ipsilateral lung V30 <15% with no specific constraint on contralateral lung", "Total lung V5 <40% while relaxing V20 and MLD constraints", "Heart V30 <30% with no further reduction in lung dose beyond standard constraints"], "answer": "A", "answer_index": 0, "explanation": "In patients with severe underlying ILD, data show the mean lung dose is the best single predictor of lethal pneumonitis; keeping MLD as low as possible (often <10 Gy) is paramount, even if cardiac doses increase somewhat. V20 (B) is important but less predictive in ILD compared with MLD. Ipsilateral V30 constraints (C) and V5 (D) are less strongly tied to high-grade pneumonitis. Prioritizing heart sparing (E) over lung constraints is inappropriate in a patient at extreme pulmonary risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes a 68-year-old man with locally advanced distal esophageal adenocarcinoma receiving neoadjuvant chemoradiation who has severe baseline ILD (UIP pattern, DLCO 35%). The question asks which planning constraint most reduces fatal radiation pneumonitis risk. Key discriminating findings: severe pre-existing ILD with markedly reduced DLCO creates extreme baseline pulmonary vulnerability. The clinical problem is prioritizing the single most critical dosimetric constraint to minimize lethal pneumonitis in this high-risk patient. Option A (MLD <10 Gy) is the keyed answer and is defensible: retrospective data in ILD patients show mean lung dose correlates most strongly with severe/fatal pneumonitis, and aggressive MLD reduction is recommended even at the expense of modest cardiac dose increases. Option B (V20 <20%) addresses an important constraint but V20 is less predictive than MLD in ILD patients. Option C (ipsilateral V30) focuses on one lung without addressing total lung exposure. Option D (V5 <40%) targets low-dose spillage, which is less strongly associated with high-grade pneumonitis than intermediate-dose metrics. Option E inappropriately prioritizes cardiac over pulmonary constraints in a patient whose limiting toxicity risk is pulmonary. No logical flaws; the stem provides sufficient detail to identify MLD as the priority metric in severe ILD. Medical accuracy is high; aligns with radiation oncology literature on ILD and pneumonitis risk. Minimal fix: none needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 68-year-old man with locally advanced distal esophageal adenocarcinoma receiving neoadjuvant chemoradiation who has severe baseline ILD (UIP pattern, DLCO 35%). The question asks which planning constraint most reduces fatal radiation pneumonitis risk. Key discriminating findings: severe pre-existing ILD with markedly reduced DLCO creates extreme baseline pulmonary vulnerability. The clinical problem is prioritizing the single most critical dosimetric constraint to minimize lethal pneumonitis in this high-risk patient. Option A (MLD <10 Gy) is the keyed answer and is defensible: retrospective data in ILD patients show mean lung dose correlates most strongly with severe/fatal pneumonitis, and aggressive MLD reduction is recommended even at the expense of modest cardiac dose increases. Option B (V20 <20%) addresses an important constraint but V20 is less predictive than MLD in ILD patients. Option C (ipsilateral V30) focuses on one lung without addressing total lung exposure. Option D (V5 <40%) targets low-dose spillage, which is less strongly associated with high-grade pneumonitis than intermediate-dose metrics. Option E inappropriately prioritizes cardiac over pulmonary constraints in a patient whose limiting toxicity risk is pulmonary. No logical flaws; the stem provides sufficient detail to identify MLD as the priority metric in severe ILD. Medical accuracy is high; aligns with radiation oncology literature on ILD and pneumonitis risk. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-004", "question": "A 63-year-old woman undergoes right upper lobectomy via VATS for a 2.8-cm peripheral squamous cell carcinoma. On postoperative day 5 she develops acute dyspnea and subcutaneous emphysema. Chest CT shows a large posterior membranous tracheal defect 2 cm above the carina communicating with a loculated right pleural air collection. Bronchoscopy confirms a 1.5-cm full-thickness laceration with necrotic edges in a fragile, steroid-exposed airway. The right main bronchus is intact; there is no mediastinitis and she is hemodynamically stable but ventilator dependent. Which operative strategy provides the best chance of durable repair and respiratory recovery?", "options": ["Primary end-to-end tracheal resection with anastomosis and neck flexion, without tissue interposition", "Right posterolateral thoracotomy with direct tracheal defect closure reinforced by a pedicled intercostal muscle flap", "Cervical approach with placement of a covered tracheal stent and no open repair", "Right thoracotomy with tracheal defect closure buttressed by a pedicled latissimus dorsi flap and distal tracheostomy below the repair", "Clamshell thoracotomy with carinal resection and reconstruction to isolate the injured segment"], "answer": "B", "answer_index": 1, "explanation": "A posterior distal tracheal laceration communicating with the ipsilateral pleura after lobectomy is best approached via thoracotomy with direct repair and vascularized intercostal muscle buttress, preserving remaining lung and avoiding extensive resection. Circumferential resection (A, E) is excessive and risky in a fragile airway. Covered stenting alone (C) in a full-thickness laceration with necrotic edges risks dehiscence and mediastinitis. Latissimus flap plus distal tracheostomy (D) is more morbid and generally unnecessary compared with intercostal muscle reinforcement.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 1.5-cm full-thickness posterior membranous tracheal laceration 2 cm above the carina in a steroid-exposed patient post-lobectomy, with necrotic edges, loculated pleural air, and ventilator dependence but no mediastinitis. Key discriminators: (1) distal tracheal location accessible via thoracotomy, (2) full-thickness defect with compromised tissue requiring reinforcement, (3) stable patient without mediastinitis, (4) intact right main bronchus. Option B (thoracotomy with direct repair plus intercostal muscle flap) is the standard approach for iatrogenic distal tracheal injuries—provides direct access, primary closure, and well-vascularized tissue buttress for fragile/steroid-exposed tissue. Option A (circumferential resection-anastomosis) is excessive for a focal laceration and carries high morbidity in compromised tissue. Option C (stent alone) inadequately addresses full-thickness necrotic defect and risks persistent leak/mediastinitis. Option D (latissimus plus tracheostomy) adds unnecessary morbidity; intercostal muscle is sufficient and tracheostomy below repair is not indicated. Option E (carinal resection) is vastly excessive for injury 2 cm above carina. The item is logically valid with clear stem support for B. Medical accuracy is excellent—reflects current thoracic surgery principles for iatrogenic tracheal injury management. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 1.5-cm full-thickness posterior membranous tracheal laceration 2 cm above the carina in a steroid-exposed patient post-lobectomy, with necrotic edges, loculated pleural air, and ventilator dependence but no mediastinitis. Key discriminators: (1) distal tracheal location accessible via thoracotomy, (2) full-thickness defect with compromised tissue requiring reinforcement, (3) stable patient without mediastinitis, (4) intact right main bronchus. Option B (thoracotomy with direct repair plus intercostal muscle flap) is the standard approach for iatrogenic distal tracheal injuries—provides direct access, primary closure, and well-vascularized tissue buttress for fragile/steroid-exposed tissue. Option A (circumferential resection-anastomosis) is excessive for a focal laceration and carries high morbidity in compromised tissue. Option C (stent alone) inadequately addresses full-thickness necrotic defect and risks persistent leak/mediastinitis. Option D (latissimus plus tracheostomy) adds unnecessary morbidity; intercostal muscle is sufficient and tracheostomy below repair is not indicated. Option E (carinal resection) is vastly excessive for injury 2 cm above carina. The item is logically valid with clear stem support for B. Medical accuracy is excellent—reflects current thoracic surgery principles for iatrogenic tracheal injury management. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-005", "question": "A 72-year-old man with prior left common femoral endarterectomy and iliac stenting presents with limb-threatening ischemia of the left leg (Rutherford class 5). Angiography shows occluded left external iliac stent and a heavily calcified common femoral artery with poor clamp sites. The profunda femoris is patent with robust collaterals; the superficial femoral artery (SFA) is chronically occluded. Aortobifemoral bypass is contraindicated due to prior hostile laparotomy and significant cardiopulmonary comorbidity. Which revascularization strategy most reliably restores durable inflow to the profunda with acceptable operative risk?", "options": ["Endovascular recanalization and relining of the external iliac stent only, without addressing the common femoral artery", "Retroperitoneal ilio-profunda bypass from the ipsilateral common iliac artery to the profunda femoris artery", "Axillo-bifemoral bypass using an 8-mm ringed PTFE graft with proximal hood anastomosis to the axillary artery", "Femoral-femoral crossover bypass from the contralateral common femoral artery to the ipsilateral profunda femoris artery", "Hybrid repair with endovascular iliac stent relining plus open common femoral endarterectomy and patch angioplasty to the profunda origin"], "answer": "E", "answer_index": 4, "explanation": "A hybrid approach-iliac stent relining to restore inflow plus open common femoral endarterectomy/patch to the profunda-directly corrects both inflow and the key outflow vessel while avoiding aortic surgery. Isolated iliac relining (A) leaves the diseased CFA uncorrected. Ilio-profunda bypass (B) is more invasive than necessary in a hostile abdomen. Axillo-bifemoral (C) and fem-fem crossover (D) ignore the ipsilateral inflow lesion and are less durable or anatomically suboptimal in this context.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 72-year-old with Rutherford class 5 limb-threatening ischemia, occluded external iliac stent, heavily calcified CFA with poor clamp sites, patent profunda with collaterals, chronically occccluded SFA, and contraindications to aortobifemoral bypass (hostile abdomen, cardiopulmonary comorbidity). The clinical problem is selecting optimal revascularization for durable profunda inflow with acceptable operative risk. Key discriminating findings: (1) both iliac inflow and CFA outflow are diseased, (2) profunda is the only viable outflow target, (3) patient is high-risk for major open surgery. Option E (hybrid: endovascular iliac relining + open CFA endarterectomy/patch to profunda) addresses both lesions with minimal invasiveness—the iliac component restores inflow endovascularly while limited groin exposure corrects the CFA/profunda origin, avoiding hostile abdomen. Option A fails to address diseased CFA. Option B (ilio-profunda bypass) requires retroperitoneal dissection in hostile abdomen, excessive for this scenario. Option C (axillo-bifemoral) ignores treatable ipsilateral inflow and has inferior patency. Option D (fem-fem crossover) leaves ipsilateral iliac occlusion unaddressed and depends on contralateral system. The keyed answer is medically sound, reflecting contemporary hybrid vascular practice for complex multilevel disease in high-risk patients. No logical flaws or medical inaccuracies identified. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 72-year-old with Rutherford class 5 limb-threatening ischemia, occluded external iliac stent, heavily calcified CFA with poor clamp sites, patent profunda with collaterals, chronically occccluded SFA, and contraindications to aortobifemoral bypass (hostile abdomen, cardiopulmonary comorbidity). The clinical problem is selecting optimal revascularization for durable profunda inflow with acceptable operative risk. Key discriminating findings: (1) both iliac inflow and CFA outflow are diseased, (2) profunda is the only viable outflow target, (3) patient is high-risk for major open surgery. Option E (hybrid: endovascular iliac relining + open CFA endarterectomy/patch to profunda) addresses both lesions with minimal invasiveness—the iliac component restores inflow endovascularly while limited groin exposure corrects the CFA/profunda origin, avoiding hostile abdomen. Option A fails to address diseased CFA. Option B (ilio-profunda bypass) requires retroperitoneal dissection in hostile abdomen, excessive for this scenario. Option C (axillo-bifemoral) ignores treatable ipsilateral inflow and has inferior patency. Option D (fem-fem crossover) leaves ipsilateral iliac occlusion unaddressed and depends on contralateral system. The keyed answer is medically sound, reflecting contemporary hybrid vascular practice for complex multilevel disease in high-risk patients. No logical flaws or medical inaccuracies identified. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-006", "question": "A 45-year-old woman with a 1.7-cm left adrenal incidentaloma has mild hypertension and intermittent headaches. She is on a thiazide diuretic. Labs show: K 3.3 mmol/L, plasma aldosterone 15 ng/dL, plasma renin activity 0.1 ng/mL/h (suppressed), and aldosterone-renin ratio (ARR) of 150 (elevated). Confirmatory saline suppression test is borderline. Adrenal vein sampling (AVS) without cosyntropin stimulation reveals: cortisol-corrected aldosterone lateralization index (LI) of 2.2, but contralateral suppression index <0.3. Which is the most appropriate next step in management?", "options": ["Left laparoscopic adrenalectomy, given imaging-concordant unilateral lesion and contralateral suppression", "Continue medical therapy with mineralocorticoid receptor antagonists because lateralization index is below traditional cutoff", "Repeat AVS with cosyntropin stimulation to clarify lateralization before deciding on surgery", "Proceed to partial (cortical-sparing) resection of the left adrenal nodule to preserve adrenal function", "Observation without intervention, as results suggest nonfunctioning incidentaloma"], "answer": "A", "answer_index": 0, "explanation": "Current AVS interpretation emphasizes both lateralization and contralateral suppression; a low contralateral aldosterone/cortisol ratio (<0.3) strongly indicates unilateral disease even with modest LI, especially with concordant imaging and biochemical primary aldosteronism. Medical therapy (B) or observation (E) ignores resectable unilateral disease. Repeating AVS (C) is unnecessary given clear suppression. Partial adrenalectomy (D) is not standard for unilateral aldosterone-producing adenomas and risks recurrence.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 45-year-old woman with biochemical primary aldosteronism (elevated ARR, suppressed renin, hypokalemia) and a 1.7-cm left adrenal nodule. The critical discriminating finding is AVS showing contralateral suppression index <0.3, which strongly indicates unilateral aldosterone hypersecretion even though the lateralization index of 2.2 is below the traditional cutoff of 4. Current expert consensus emphasizes that contralateral suppression is a robust indicator of unilateral disease, particularly when imaging is concordant. Choice A (left adrenalectomy) is the appropriate management for surgically correctable unilateral primary aldosteronism. Choice B incorrectly prioritizes the LI over contralateral suppression. Choice C is unnecessary given clear contralateral suppression. Choice D (partial adrenalectomy) is not standard for aldosterone-producing adenomas and risks incomplete resection. Choice E ignores confirmed functional disease. The item is logically valid with a unique best answer supported by modern AVS interpretation guidelines. Medical accuracy is excellent, reflecting current understanding that contralateral suppression can confirm lateralization independent of LI thresholds. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 45-year-old woman with biochemical primary aldosteronism (elevated ARR, suppressed renin, hypokalemia) and a 1.7-cm left adrenal nodule. The critical discriminating finding is AVS showing contralateral suppression index <0.3, which strongly indicates unilateral aldosterone hypersecretion even though the lateralization index of 2.2 is below the traditional cutoff of 4. Current expert consensus emphasizes that contralateral suppression is a robust indicator of unilateral disease, particularly when imaging is concordant. Choice A (left adrenalectomy) is the appropriate management for surgically correctable unilateral primary aldosteronism. Choice B incorrectly prioritizes the LI over contralateral suppression. Choice C is unnecessary given clear contralateral suppression. Choice D (partial adrenalectomy) is not standard for aldosterone-producing adenomas and risks incomplete resection. Choice E ignores confirmed functional disease. The item is logically valid with a unique best answer supported by modern AVS interpretation guidelines. Medical accuracy is excellent, reflecting current understanding that contralateral suppression can confirm lateralization independent of LI thresholds. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-007", "question": "A 63-year-old man with compensated cirrhosis (Child-Pugh A, MELD 9) has a 2.3-cm hepatocellular carcinoma (HCC) in segment VII adjacent to the right hepatic vein and diaphragm. He has portal hypertension with platelets 70,000/µL, small varices, and HVPG 13 mmHg. Liver function is preserved; he is not yet listed for transplant due to social issues. Which management offers the best balance of long-term oncologic control and hepatic reserve preservation?", "options": ["Open right posterior sectionectomy including segment VII and part of VIII", "Laparoscopic wedge resection of segment VII tumor with Pringle maneuver", "Ultrasound-guided percutaneous radiofrequency ablation (RFA) of the lesion", "Transarterial chemoembolization (TACE) followed by reassessment for ablation or resection", "Listing for liver transplantation without locoregional therapy until a donor becomes available"], "answer": "C", "answer_index": 2, "explanation": "For a solitary ≤3-cm HCC in a cirrhotic liver with significant portal hypertension and thrombocytopenia, percutaneous ablation achieves local control comparable to resection with lower risk of hepatic decompensation. Major or even limited resection (A, B) carries high risk in portal hypertension (HVPG >10 mmHg). TACE (D) is inferior to curative-intent ablation for small lesions. Delayed transplant without bridging (E) risks progression beyond criteria and prevents near-term curative local control.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 2.3-cm solitary HCC in a Child-Pugh A cirrhotic with clinically significant portal hypertension (HVPG 13 mmHg, platelets 70k, varices). Key discriminating findings: preserved synthetic function but portal hypertension contraindicates resection; tumor size/location suitable for ablation; not yet transplant-listed. Option C (RFA) is the established best answer: for single HCC ≤3 cm in compensated cirrhosis with portal hypertension, ablation achieves curative-intent local control with minimal hepatic injury risk. Options A/B (resection) carry prohibitive decompensation risk when HVPG >10 mmHg and platelets are low. Option D (TACE) is palliative, not curative-intent for small resectable/ablatable lesions per BCLC staging. Option E (no bridging therapy) risks tumor progression beyond Milan criteria while awaiting transplant, which is not imminent due to social issues. The item correctly applies Barcelona Clinic Liver Cancer guidelines and portal hypertension contraindications to resection. Medical accuracy is high: ablation vs resection decision-making aligns with current hepatology consensus. No logical flaws; stem provides sufficient detail to discriminate among options. Minimal fix: none needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 2.3-cm solitary HCC in a Child-Pugh A cirrhotic with clinically significant portal hypertension (HVPG 13 mmHg, platelets 70k, varices). Key discriminating findings: preserved synthetic function but portal hypertension contraindicates resection; tumor size/location suitable for ablation; not yet transplant-listed. Option C (RFA) is the established best answer: for single HCC ≤3 cm in compensated cirrhosis with portal hypertension, ablation achieves curative-intent local control with minimal hepatic injury risk. Options A/B (resection) carry prohibitive decompensation risk when HVPG >10 mmHg and platelets are low. Option D (TACE) is palliative, not curative-intent for small resectable/ablatable lesions per BCLC staging. Option E (no bridging therapy) risks tumor progression beyond Milan criteria while awaiting transplant, which is not imminent due to social issues. The item correctly applies Barcelona Clinic Liver Cancer guidelines and portal hypertension contraindications to resection. Medical accuracy is high: ablation vs resection decision-making aligns with current hepatology consensus. No logical flaws; stem provides sufficient detail to discriminate among options. Minimal fix: none needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-008", "question": "A 39-year-old man presents with recurrent pancreatitis and is found to have a 2.5-cm enhancing mass in the pancreatic head that encases the intrapancreatic common bile duct, with upstream dilatation but no vascular involvement. EUS-FNA is nondiagnostic twice. CA 19-9 is normal. IgG4 level is mildly elevated at 180 mg/dL (ULN 135). CT shows a capsule-like rim around the lesion and diffuse, sausage-shaped enlargement of the gland. Which management approach is most appropriate?", "options": ["Trial of high-dose corticosteroids with close radiologic follow-up before considering surgery", "Pancreaticoduodenectomy because focal autoimmune pancreatitis cannot be reliably distinguished from adenocarcinoma", "Repeat EUS-FNA with core needle and flow cytometry to exclude lymphoma", "Observation alone with serial imaging in 6 months given low CA 19-9 and mild symptoms", "ERCP with biliary brushing cytology and stent placement, with surgery only if cytology is positive"], "answer": "A", "answer_index": 0, "explanation": "Imaging findings (capsule-like rim, sausage-shaped gland) and elevated IgG4 strongly suggest type 1 autoimmune pancreatitis; a steroid trial with close monitoring is accepted to avoid unnecessary Whipple when malignancy is not strongly supported. Immediate pancreaticoduodenectomy (B) is premature. Repeat biopsy (C) is less helpful given characteristic features. Observation alone (D) ignores ongoing pancreatitis and biliary obstruction. ERCP cytology (E) has low sensitivity and does not treat underlying inflammatory disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 39-year-old man with recurrent pancreatitis, a 2.5-cm pancreatic head mass encasing the CBD with upstream dilatation, twice-nondiagnostic EUS-FNA, normal CA 19-9, mildly elevated IgG4 (180 mg/dL, ULN 135), and imaging showing capsule-like rim and sausage-shaped gland enlargement. Key discriminating findings favor autoimmune pancreatitis (AIP): capsule-like rim, diffuse gland enlargement, elevated IgG4, normal CA 19-9. However, the IgG4 elevation is only mild (180 vs 135), and twice-nondiagnostic biopsies raise concern that malignancy cannot be excluded. Both A (steroid trial) and B (pancreaticoduodenectomy) are defensible. Option A follows the approach for probable AIP with steroid trial and monitoring, which is standard when imaging/serology suggest AIP. Option B reflects the reality that focal AIP mimicking pancreatic cancer with nondiagnostic biopsies often warrants surgery to exclude malignancy, especially with CBD encasement—a concerning feature. The stem does not provide sufficient certainty (e.g., very high IgG4 >280, other organ involvement, or definitive histology) to make steroid trial unequivocally safer than surgery. Medical accuracy: The teaching point is reasonable, but real-world practice varies; some centers would proceed to surgery given twice-failed biopsies and CBD encasement. Minimal fix: Specify higher IgG4 level (>280 mg/dL) or add other organ involvement to make AIP diagnosis more certain and steroid trial clearly preferred.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 39-year-old man with recurrent pancreatitis, a 2.5-cm pancreatic head mass encasing the CBD with upstream dilatation, twice-nondiagnostic EUS-FNA, normal CA 19-9, mildly elevated IgG4 (180 mg/dL, ULN 135), and imaging showing capsule-like rim and sausage-shaped gland enlargement. Key discriminating findings favor autoimmune pancreatitis (AIP): capsule-like rim, diffuse gland enlargement, elevated IgG4, normal CA 19-9. However, the IgG4 elevation is only mild (180 vs 135), and twice-nondiagnostic biopsies raise concern that malignancy cannot be excluded. Both A (steroid trial) and B (pancreaticoduodenectomy) are defensible. Option A follows the approach for probable AIP with steroid trial and monitoring, which is standard when imaging/serology suggest AIP. Option B reflects the reality that focal AIP mimicking pancreatic cancer with nondiagnostic biopsies often warrants surgery to exclude malignancy, especially with CBD encasement—a concerning feature. The stem does not provide sufficient certainty (e.g., very high IgG4 >280, other organ involvement, or definitive histology) to make steroid trial unequivocally safer than surgery. Medical accuracy: The teaching point is reasonable, but real-world practice varies; some centers would proceed to surgery given twice-failed biopsies and CBD encasement. Minimal fix: Specify higher IgG4 level (>280 mg/dL) or add other organ involvement to make AIP diagnosis more certain and steroid trial clearly preferred.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-009", "question": "A 26-year-old man presents with splenomegaly, hemoglobin 9.8 g/dL, platelets 130,000/µL, and leukocytes 5,200/µL. Peripheral smear shows tear-drop cells and leukoerythroblastosis. Bone marrow biopsy is markedly fibrotic with 1-2% blasts; JAK2, CALR, and MPL mutations are negative; next-generation sequencing reveals an isolated ASXL1 mutation. Cytogenetics are normal. He is transfusion independent but symptomatic from splenomegaly. DIPSS-plus score indicates intermediate-2 risk primary myelofibrosis. His 10/10 HLA-matched sibling donor is available. Which is the most appropriate management strategy?", "options": ["Begin ruxolitinib and defer allogeneic stem cell transplantation until he becomes transfusion dependent", "Proceed to allogeneic stem cell transplantation in first chronic phase despite triple-negative driver status", "Observation with serial monitoring; ASXL1 mutation alone does not justify early transplant", "Splenectomy followed by hydroxyurea cytoreduction to delay transplantation", "Ruxolitinib bridge therapy for 3-6 months to reduce spleen size, then proceed to planned allogeneic transplantation"], "answer": "E", "answer_index": 4, "explanation": "Intermediate-2 risk myelofibrosis in a young patient with an available donor warrants allogeneic transplant; bridging with ruxolitinib can reduce spleen size and improve conditioning tolerance without compromising transplant timing. Deferring transplant (A, C) risks disease progression. Splenectomy (D) before transplant is reserved for select cases due to morbidity. Immediate transplant without JAK inhibitor optimization (B) may lead to worse peri-transplant outcomes in massively enlarged spleens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 26-year-old with intermediate-2 risk primary myelofibrosis (PMF) by DIPSS-plus, symptomatic splenomegaly, triple-negative driver mutations, ASXL1 mutation (adverse prognostic marker), and an available 10/10 HLA-matched sibling donor. Key discriminating findings: young age, intermediate-2 risk, symptomatic splenomegaly, available matched donor, transfusion independence. The clinical problem asks for optimal management strategy balancing transplant timing with peri-transplant optimization. Option E (ruxolitinib bridge 3-6 months then transplant) is the current standard: JAK inhibitor therapy reduces spleen size, improves performance status, and optimizes transplant outcomes while maintaining appropriate timing for intermediate-2 risk disease. Option A inappropriately defers definitive therapy despite transplant indication. Option B risks worse peri-transplant morbidity with massive splenomegaly. Option C underestimates intermediate-2 risk significance. Option D (splenectomy) adds surgical morbidity and is not standard pre-transplant. The keyed answer aligns with contemporary myelofibrosis management guidelines emphasizing early transplant for intermediate-2/high-risk disease in transplant-eligible patients, with ruxolitinib bridging to optimize outcomes. No logical flaws or medical inaccuracies identified. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 26-year-old with intermediate-2 risk primary myelofibrosis (PMF) by DIPSS-plus, symptomatic splenomegaly, triple-negative driver mutations, ASXL1 mutation (adverse prognostic marker), and an available 10/10 HLA-matched sibling donor. Key discriminating findings: young age, intermediate-2 risk, symptomatic splenomegaly, available matched donor, transfusion independence. The clinical problem asks for optimal management strategy balancing transplant timing with peri-transplant optimization. Option E (ruxolitinib bridge 3-6 months then transplant) is the current standard: JAK inhibitor therapy reduces spleen size, improves performance status, and optimizes transplant outcomes while maintaining appropriate timing for intermediate-2 risk disease. Option A inappropriately defers definitive therapy despite transplant indication. Option B risks worse peri-transplant morbidity with massive splenomegaly. Option C underestimates intermediate-2 risk significance. Option D (splenectomy) adds surgical morbidity and is not standard pre-transplant. The keyed answer aligns with contemporary myelofibrosis management guidelines emphasizing early transplant for intermediate-2/high-risk disease in transplant-eligible patients, with ruxolitinib bridging to optimize outcomes. No logical flaws or medical inaccuracies identified. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-010", "question": "A 31-year-old woman with systemic lupus erythematosus, class IV lupus nephritis, and high-titer anti-dsDNA presents with a 4-week history of progressive symmetric lower extremity weakness, areflexia, and sensory loss. NCS/EMG show a demyelinating polyneuropathy consistent with CIDP. She is on prednisone 10 mg daily and hydroxychloroquine. Creatinine is 1.3 mg/dL; she has nephrotic-range proteinuria. Which immunologic treatment strategy best balances disease control and long-term toxicity?", "options": ["High-dose IV methylprednisolone pulses followed by oral prednisone 1 mg/kg for both CIDP and lupus nephritis", "IVIG monthly for CIDP plus increase prednisone to 0.5 mg/kg, with no other agents", "Rituximab-based regimen targeting both CIDP and lupus nephritis with tapering of steroids", "Cyclophosphamide induction followed by azathioprine maintenance for lupus and CIDP", "Plasma exchange for CIDP plus mycophenolate mofetil for lupus nephritis"], "answer": "C", "answer_index": 2, "explanation": "Rituximab has efficacy in both CIDP (especially autoimmune-mediated forms) and proliferative lupus nephritis, allowing steroid sparing and addressing shared B-cell pathogenesis. High-dose steroids alone (A, B) worsen long-term toxicity and may be insufficient for nephritis. Cyclophosphamide (D) carries more gonadal and malignancy risk in a young woman. Plasmapheresis (E) gives transient CIDP benefit but does not control chronic B-cell-driven lupus nephritis as effectively as rituximab-based regimens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 31-year-old woman with active class IV lupus nephritis (nephrotic-range proteinuria, Cr 1.3) and new CIDP requiring dual immunosuppression. Key discriminating findings: young woman (fertility concerns), active proliferative nephritis, demyelinating neuropathy, already on inadequate immunosuppression. The question asks for treatment balancing disease control and long-term toxicity. Main logical issues: (1) The stem does not specify whether rituximab is an accepted first-line agent for CIDP in this context—CIDP treatment guidelines primarily support IVIG, steroids, or plasma exchange as first-line, with rituximab reserved for refractory cases. (2) Multiple options are defensible: Option C (rituximab) assumes off-label CIDP efficacy; Option E (PLEX + MMF) uses established therapies—MMF is standard for lupus nephritis maintenance, and PLEX is guideline-supported for CIDP. (3) The item requires assuming rituximab's CIDP efficacy equals or exceeds standard therapies, which is not universally accepted. Medical accuracy issues: Rituximab for CIDP remains investigational/off-label in most guidelines; the rationale overstates its established role. Minimal fix: Specify that standard CIDP therapies have failed or add evidence supporting rituximab as first-line for autoimmune CIDP variants.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 31-year-old woman with active class IV lupus nephritis (nephrotic-range proteinuria, Cr 1.3) and new CIDP requiring dual immunosuppression. Key discriminating findings: young woman (fertility concerns), active proliferative nephritis, demyelinating neuropathy, already on inadequate immunosuppression. The question asks for treatment balancing disease control and long-term toxicity. Main logical issues: (1) The stem does not specify whether rituximab is an accepted first-line agent for CIDP in this context—CIDP treatment guidelines primarily support IVIG, steroids, or plasma exchange as first-line, with rituximab reserved for refractory cases. (2) Multiple options are defensible: Option C (rituximab) assumes off-label CIDP efficacy; Option E (PLEX + MMF) uses established therapies—MMF is standard for lupus nephritis maintenance, and PLEX is guideline-supported for CIDP. (3) The item requires assuming rituximab's CIDP efficacy equals or exceeds standard therapies, which is not universally accepted. Medical accuracy issues: Rituximab for CIDP remains investigational/off-label in most guidelines; the rationale overstates its established role. Minimal fix: Specify that standard CIDP therapies have failed or add evidence supporting rituximab as first-line for autoimmune CIDP variants.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-011", "question": "A 27-year-old woman sustains a severe crush-avulsion injury to her dominant right forearm in an industrial press. There is segmental loss of the ulnar artery, ulnar nerve (6 cm gap at the wrist), and extensive soft-tissue loss over the volar-ulnar forearm with exposed flexor tendons; radial artery and median nerve are intact. Hand perfusion is marginal via the radial artery. Debridement leaves a 12 × 8 cm wound and nonrepairable FDS/FDP to ring and small fingers. Considering function and reconstructive ladder, what is the optimal reconstructive strategy in a single stage?", "options": ["Local rotational fasciocutaneous flap with reversed interpositional saphenous vein graft for ulnar artery and autologous sural nerve cable grafts for ulnar nerve", "Free anterolateral thigh (ALT) flap with flow-through reconstruction of the ulnar artery and nerve coaptation via sural nerve graft", "Split-thickness skin graft over the exposed tendons after tendon shortening and radial artery-only perfusion", "Pedicled groin flap for soft-tissue coverage and delayed ulnar nerve grafting once the wound bed is stable", "Free radial forearm flap from the contralateral limb including cephalic vein for venous outflow and ulnar nerve primary end-to-end repair under tension"], "answer": "B", "answer_index": 1, "explanation": "A free ALT flap can provide robust soft-tissue coverage and can be configured as a flow-through flap to reconstitute the ulnar artery while allowing concurrent ulnar nerve cable grafting, optimizing perfusion and nerve regeneration in one stage. Local rotational flaps (A) are insufficient for the large defect and lack flow-through capabilities. Skin graft alone (C) is inadequate over exposed tendons and does not restore artery/nerve. Staged groin flap (D) delays nerve repair. A contralateral radial forearm flap (E) sacrifices a major artery and cannot provide tension-free primary nerve repair.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best. The stem describes a complex forearm injury requiring simultaneous soft-tissue coverage (12×8 cm defect with exposed tendons), vascular reconstruction (ulnar artery loss with marginal hand perfusion), and nerve repair (6 cm ulnar nerve gap). Key discriminators: large defect size, need for arterial flow restoration, 6 cm nerve gap precluding tension-free repair, and single-stage requirement. Option B (free ALT with flow-through) addresses all components: adequate tissue bulk for large defect, flow-through capability restores ulnar artery perfusion augmenting marginal radial supply, and permits concurrent nerve cable grafting. Option A fails because local flaps cannot cover 12×8 cm reliably and reversed vein grafts lack flow-through advantages. Option C is inadequate—skin grafts fail over exposed tendons without vascularized coverage. Option D violates single-stage requirement by delaying nerve repair. Option E sacrifices contralateral radial artery (unacceptable donor morbidity) and cannot achieve tension-free repair across 6 cm gap. Medical accuracy is high; flow-through free flaps are established for combined defects. Minimal fix: none needed; item is well-constructed with clear discriminators favoring one answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. The stem describes a complex forearm injury requiring simultaneous soft-tissue coverage (12×8 cm defect with exposed tendons), vascular reconstruction (ulnar artery loss with marginal hand perfusion), and nerve repair (6 cm ulnar nerve gap). Key discriminators: large defect size, need for arterial flow restoration, 6 cm nerve gap precluding tension-free repair, and single-stage requirement. Option B (free ALT with flow-through) addresses all components: adequate tissue bulk for large defect, flow-through capability restores ulnar artery perfusion augmenting marginal radial supply, and permits concurrent nerve cable grafting. Option A fails because local flaps cannot cover 12×8 cm reliably and reversed vein grafts lack flow-through advantages. Option C is inadequate—skin grafts fail over exposed tendons without vascularized coverage. Option D violates single-stage requirement by delaying nerve repair. Option E sacrifices contralateral radial artery (unacceptable donor morbidity) and cannot achieve tension-free repair across 6 cm gap. Medical accuracy is high; flow-through free flaps are established for combined defects. Minimal fix: none needed; item is well-constructed with clear discriminators favoring one answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-012", "question": "A 54-year-old man with a 2.2-cm pituitary macroadenoma causing acromegaly undergoes endoscopic endonasal resection. Postoperative day 1 labs show serum sodium 142 mmol/L and urine output 3.5 L/day. On day 7, sodium is 128 mmol/L with serum osmolality 265 mOsm/kg and urine osmolality 600 mOsm/kg; he is clinically euvolemic. Morning cortisol is 15 µg/dL. On day 12, sodium falls to 118 mmol/L despite fluid restriction, and he becomes confused; serum osmolality 250 mOsm/kg, urine osmolality 750 mOsm/kg. MRI shows no new findings. Which mechanism best explains this delayed worsening hyponatremia?", "options": ["Persistent syndrome of inappropriate antidiuretic hormone secretion (SIADH) from hypothalamic neuronal injury", "Triphasic water balance disorder with transition from SIADH phase to late-phase permanent diabetes insipidus", "Cerebral salt wasting due to subclinical subarachnoid hemorrhage during surgery", "Reset osmostat due to chronic hyponatremia from preoperative growth hormone excess", "Glucocorticoid deficiency from delayed postoperative hypopituitarism"], "answer": "A", "answer_index": 0, "explanation": "The typical triphasic pattern after pituitary surgery is early DI, then SIADH-related hyponatremia around days 5-10; persistent, severe, euvolemic hyponatremia with high urine osmolality is most consistent with sustained SIADH. Transition to DI (B) would cause hypernatremia and dilute urine. Cerebral salt wasting (C) would show hypovolemia and high urine sodium but is rare here. Reset osmostat (D) would not present with acute confusion at Na 118. Cortisol deficiency (E) is unlikely with normal morning cortisol.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a biphasic pattern: initial polyuria (day 1, likely transient DI), then progressive hyponatremia (days 7-12) with euvolemia and concentrated urine. Key discriminating findings: euvolemic hyponatremia, high urine osmolality (600→750), normal morning cortisol (15 µg/dL), worsening despite fluid restriction. The keyed answer (A: persistent SIADH from hypothalamic injury) fits the euvolemic hyponatremia with concentrated urine. However, option E (glucocorticoid deficiency) is equally defensible: a single morning cortisol of 15 µg/dL does NOT exclude secondary adrenal insufficiency in the postoperative stress context—dynamic testing (cosyntropin stimulation or ACTH level) would be required. Cortisol deficiency causes euvolemic hyponatremia with concentrated urine identical to SIADH. The rationale dismisses E based solely on 'normal morning cortisol,' but 15 µg/dL may be inadequate for surgical stress, and the stem lacks ACTH or stimulation test data to definitively rule out hypopituitarism. Main logical issue: underspecified cortisol assessment creates two defensible answers (U→M). Medical accuracy: mostly sound but oversimplifies cortisol interpretation. Minimal fix: add 'ACTH <5 pg/mL and cosyntropin-stimulated cortisol 25 µg/dL' to exclude adrenal insufficiency definitively.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a biphasic pattern: initial polyuria (day 1, likely transient DI), then progressive hyponatremia (days 7-12) with euvolemia and concentrated urine. Key discriminating findings: euvolemic hyponatremia, high urine osmolality (600→750), normal morning cortisol (15 µg/dL), worsening despite fluid restriction. The keyed answer (A: persistent SIADH from hypothalamic injury) fits the euvolemic hyponatremia with concentrated urine. However, option E (glucocorticoid deficiency) is equally defensible: a single morning cortisol of 15 µg/dL does NOT exclude secondary adrenal insufficiency in the postoperative stress context—dynamic testing (cosyntropin stimulation or ACTH level) would be required. Cortisol deficiency causes euvolemic hyponatremia with concentrated urine identical to SIADH. The rationale dismisses E based solely on 'normal morning cortisol,' but 15 µg/dL may be inadequate for surgical stress, and the stem lacks ACTH or stimulation test data to definitively rule out hypopituitarism. Main logical issue: underspecified cortisol assessment creates two defensible answers (U→M). Medical accuracy: mostly sound but oversimplifies cortisol interpretation. Minimal fix: add 'ACTH <5 pg/mL and cosyntropin-stimulated cortisol 25 µg/dL' to exclude adrenal insufficiency definitively.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-013", "question": "A 69-year-old man with T2N0M0 glottic squamous cell carcinoma extending to the anterior commissure is planned for definitive radiotherapy. He is a heavy smoker with severe COPD and cannot tolerate prolonged immobilization. The radiation oncologist must choose the optimal fractionation regimen to maximize local control while minimizing acute laryngeal edema and long-term dysphagia. Which regimen best balances these goals?", "options": ["Conventional 2.0 Gy per fraction to 70 Gy over 7 weeks", "Hypofractionated 2.25 Gy per fraction to 63 Gy over 5.6 weeks", "Hyperfractionated 1.2 Gy twice daily to 79.2 Gy total dose", "Concomitant boost regimen with 1.8 Gy daily plus 1.5 Gy second daily fraction in the final 3 weeks", "Stereotactic body radiotherapy (SBRT) 7.5 Gy × 5 fractions to the glottic larynx"], "answer": "B", "answer_index": 1, "explanation": "For early to select T2 glottic cancers, modest hypofractionation (e.g., 2.25 Gy/fraction to ~63 Gy) improves local control with acceptable toxicity and shorter overall treatment time, particularly useful in patients with limited tolerance for prolonged immobilization. Conventional fractionation (A) is effective but less optimal in control and time. Hyperfractionation (C) and concomitant boost (D) increase mucosal toxicity. SBRT (E) for glottic cancer remains investigational with concerns about cartilage necrosis and voice quality.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The question asks for optimal fractionation balancing local control, acute edema minimization, and long-term dysphagia reduction in T2N0M0 glottic cancer with anterior commissure involvement. Key stem clues: T2 disease, anterior commissure extension, severe COPD limiting immobilization tolerance. The keyed answer (B, hypofractionated 2.25 Gy to 63 Gy) is defended as offering better local control with shorter treatment time. However, the stem lacks critical information: (1) whether this is T2a or T2b disease (anterior commissure involvement suggests higher-risk T2), (2) specific voice preservation priorities, and (3) the relative weight of acute versus late toxicity concerns. Option A (conventional 70 Gy) is the established standard for T2 glottic cancer with proven efficacy and is widely used. The claim that modest hypofractionation (B) definitively improves local control over conventional fractionation for T2 disease is not universally established in guidelines; evidence is mixed and context-dependent. Both A and B are defensible depending on institutional protocols and risk stratification. The item requires unstated assumptions about which outcome (shorter treatment vs. established efficacy) takes priority. Medical accuracy: The rationale overstates hypofractionation superiority for T2 disease. Minimal fix: Specify T2a disease and explicitly state that minimizing treatment duration is the primary constraint given COPD intolerance.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The question asks for optimal fractionation balancing local control, acute edema minimization, and long-term dysphagia reduction in T2N0M0 glottic cancer with anterior commissure involvement. Key stem clues: T2 disease, anterior commissure extension, severe COPD limiting immobilization tolerance. The keyed answer (B, hypofractionated 2.25 Gy to 63 Gy) is defended as offering better local control with shorter treatment time. However, the stem lacks critical information: (1) whether this is T2a or T2b disease (anterior commissure involvement suggests higher-risk T2), (2) specific voice preservation priorities, and (3) the relative weight of acute versus late toxicity concerns. Option A (conventional 70 Gy) is the established standard for T2 glottic cancer with proven efficacy and is widely used. The claim that modest hypofractionation (B) definitively improves local control over conventional fractionation for T2 disease is not universally established in guidelines; evidence is mixed and context-dependent. Both A and B are defensible depending on institutional protocols and risk stratification. The item requires unstated assumptions about which outcome (shorter treatment vs. established efficacy) takes priority. Medical accuracy: The rationale overstates hypofractionation superiority for T2 disease. Minimal fix: Specify T2a disease and explicitly state that minimizing treatment duration is the primary constraint given COPD intolerance.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-014", "question": "A 60-year-old man with severe COPD (FEV1 30% predicted) undergoes right pneumonectomy for central squamous cell carcinoma. On postoperative day 3 he develops sudden respiratory distress, hypotension, and jugular venous distention. CXR shows mediastinal shift toward the left (remaining lung side) with hyperinflation and flattened diaphragm. Emergent bronchoscopy reveals no mucus plug. Echocardiogram shows right ventricular dilation and compression of the left atrium. Which is the most likely diagnosis?", "options": ["Postpneumonectomy pulmonary edema of the remaining lung", "Early bronchopleural fistula with tension pneumothorax on the pneumonectomy side", "Acute pulmonary embolism to the left pulmonary artery", "Postpneumonectomy syndrome due to mediastinal shift and bronchial kinking", "Cardiac tamponade from postoperative hemopericardium"], "answer": "D", "answer_index": 3, "explanation": "Postpneumonectomy syndrome is due to excessive mediastinal shift causing kinking/compression of the remaining main bronchus and cardiovascular structures; though classically delayed, it can present early with hyperinflation of the remaining lung and mediastinal shift toward it, leading to RV dilation and LA compression. Pulmonary edema (A) would not explain marked mediastinal shift. Tension pneumothorax on the pneumonectomy side (B) would shift mediastinum away from the remaining lung. Massive PE (C) lacks imaging features of overinflation and shift. Tamponade (E) shows equal chamber pressures but not lung overinflation or shift.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes POD 3 sudden respiratory distress, hypotension, JVD, mediastinal shift toward the remaining (left) lung with hyperinflation, RV dilation, and LA compression. Key discriminating findings: acute presentation, shift toward remaining lung, hyperinflation, cardiovascular compromise, bronchoscopy negative for obstruction. The keyed answer (D, postpneumonectomy syndrome) is problematic because this syndrome classically presents months-to-years post-op, not acutely on POD 3. The explanation acknowledges 'though classically delayed' but provides no stem evidence supporting early presentation. Option C (acute PE) is equally defensible: massive PE to the remaining lung would cause acute RV strain/dilation, hypotension, and could produce compensatory hyperinflation; the mediastinal shift could result from acute volume redistribution and RV dilation displacing the mediastinum. The stem does not provide definitive imaging (e.g., CT angiography) to exclude PE. Both answers require assumptions: D assumes rare early postpneumonectomy syndrome; C assumes PE without confirmatory imaging. Main logical issue: two diagnoses are near-equally defensible given the acute timeframe and findings. Main medical accuracy issue: postpneumonectomy syndrome on POD 3 is atypical without explicit supporting evidence. Minimal fix: Add CT angiography results explicitly excluding PE and demonstrating bronchial kinking, or specify chronic/subacute presentation timeline.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes POD 3 sudden respiratory distress, hypotension, JVD, mediastinal shift toward the remaining (left) lung with hyperinflation, RV dilation, and LA compression. Key discriminating findings: acute presentation, shift toward remaining lung, hyperinflation, cardiovascular compromise, bronchoscopy negative for obstruction. The keyed answer (D, postpneumonectomy syndrome) is problematic because this syndrome classically presents months-to-years post-op, not acutely on POD 3. The explanation acknowledges 'though classically delayed' but provides no stem evidence supporting early presentation. Option C (acute PE) is equally defensible: massive PE to the remaining lung would cause acute RV strain/dilation, hypotension, and could produce compensatory hyperinflation; the mediastinal shift could result from acute volume redistribution and RV dilation displacing the mediastinum. The stem does not provide definitive imaging (e.g., CT angiography) to exclude PE. Both answers require assumptions: D assumes rare early postpneumonectomy syndrome; C assumes PE without confirmatory imaging. Main logical issue: two diagnoses are near-equally defensible given the acute timeframe and findings. Main medical accuracy issue: postpneumonectomy syndrome on POD 3 is atypical without explicit supporting evidence. Minimal fix: Add CT angiography results explicitly excluding PE and demonstrating bronchial kinking, or specify chronic/subacute presentation timeline.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-015", "question": "A 67-year-old woman with lifestyle-limiting claudication and rest pain in the right foot has an occluded right common iliac artery and diffuse calcific disease of the ipsilateral external iliac and common femoral arteries. The left iliac system is patent with a prior kissing stent at the aortic bifurcation. Coronary disease and frailty preclude aortobifemoral bypass. Which revascularization option best optimizes long-term patency and limb salvage?", "options": ["Right axillo-femoral bypass using an 8-mm ringed PTFE graft to the common femoral artery", "Endovascular recanalization and stenting of the occluded right common iliac plus external iliac angioplasty", "Femoral-femoral crossover bypass from left common femoral artery to right profunda femoris artery with endarterectomy of the right common femoral", "Endovascular iliac recanalization combined with drug-coated balloon angioplasty of the common femoral artery", "Ilio-femoral bypass from left common iliac artery to right common femoral artery via a retroperitoneal route"], "answer": "C", "answer_index": 2, "explanation": "Given a hostile aorta and existing left iliac stent, fem-fem crossover with CFA endarterectomy to the profunda provides robust inflow and durable outflow while avoiding major aortic surgery. Axillo-femoral bypass (A) has lower long-term patency. Pure endovascular recanalization (B, D) may be limited by heavy CFA calcification and restenosis risk, and CFA is a poor stent target. Ilio-femoral bypass (E) is more invasive and may be technically challenging given the prior kissing stent and comorbidities.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a 67-year-old woman with lifestyle-limiting claudication, rest pain (CLI), occluded right common iliac artery, diffuse calcific disease of right external iliac and common femoral arteries, patent left iliac system with prior kissing stent, and comorbidities precluding aortobifemoral bypass. Key discriminating findings: (1) CLI requiring durable revascularization, (2) hostile right iliac/CFA anatomy with heavy calcification, (3) patent left iliac donor site, (4) high surgical risk. The question asks for best long-term patency and limb salvage. Choice C (fem-fem crossover with CFA endarterectomy to profunda) is defensible: uses patent left iliac inflow, addresses CFA calcification surgically (avoiding poor stent target), targets profunda for outflow (critical for limb salvage), and avoids major aortic surgery. Alternative assessments: A (axillo-femoral) has inferior patency rates; B and D (endovascular) face technical challenges with heavily calcified CFA (poor stent zone) and high restenosis risk; E (ilio-femoral bypass) is more invasive given comorbidities and prior kissing stent. Medical accuracy: consistent with vascular surgery principles favoring fem-fem bypass for unilateral iliac occlusion with suitable contralateral donor vessel, and CFA endarterectomy for calcific disease. No contradictions or underspecification. Minimal fix: none needed; item is valid.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 67-year-old woman with lifestyle-limiting claudication, rest pain (CLI), occluded right common iliac artery, diffuse calcific disease of right external iliac and common femoral arteries, patent left iliac system with prior kissing stent, and comorbidities precluding aortobifemoral bypass. Key discriminating findings: (1) CLI requiring durable revascularization, (2) hostile right iliac/CFA anatomy with heavy calcification, (3) patent left iliac donor site, (4) high surgical risk. The question asks for best long-term patency and limb salvage. Choice C (fem-fem crossover with CFA endarterectomy to profunda) is defensible: uses patent left iliac inflow, addresses CFA calcification surgically (avoiding poor stent target), targets profunda for outflow (critical for limb salvage), and avoids major aortic surgery. Alternative assessments: A (axillo-femoral) has inferior patency rates; B and D (endovascular) face technical challenges with heavily calcified CFA (poor stent zone) and high restenosis risk; E (ilio-femoral bypass) is more invasive given comorbidities and prior kissing stent. Medical accuracy: consistent with vascular surgery principles favoring fem-fem bypass for unilateral iliac occlusion with suitable contralateral donor vessel, and CFA endarterectomy for calcific disease. No contradictions or underspecification. Minimal fix: none needed; item is valid.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-016", "question": "A 58-year-old man with a 3.8-cm right thyroid nodule and compressive symptoms undergoes total thyroidectomy. Final pathology shows a 3.8-cm encapsulated follicular-patterned lesion with capsular and focal vascular invasion in 2 of 8 intracapsular vessels, RAS-mutant, no extrathyroidal extension, and no lymph node involvement. According to modern risk stratification and evolving nomenclature, which postoperative management is most appropriate?", "options": ["Classify as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and no further therapy", "Classify as minimally invasive follicular thyroid carcinoma and recommend routine radioactive iodine ablation", "Classify as encapsulated angioinvasive follicular variant papillary thyroid carcinoma and consider RAI only if postoperative thyroglobulin is detectable", "Classify as low-risk differentiated thyroid carcinoma managed with levothyroxine to keep TSH mildly suppressed and no routine RAI", "Classify as high-risk due to vascular invasion and treat with high-dose RAI and aggressive TSH suppression (<0.1 mIU/L)"], "answer": "D", "answer_index": 3, "explanation": "Encapsulated follicular-patterned tumors with limited vascular invasion (≤4 foci) and no extrathyroidal extension are considered low-risk differentiated thyroid carcinomas; current guidelines favor TSH suppression and no routine RAI, particularly in RAS-mutated lesions without nodal disease. NIFTP (A) requires no invasion; this lesion shows both capsular and vascular invasion. Routine RAI (B, E) is excessive for low-risk tumors. Labeling as high-risk (E) is not justified by limited angioinvasion alone. Option C misclassifies the entity and overemphasizes histologic subtype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 3.8-cm encapsulated follicular-patterned thyroid lesion with capsular invasion and focal vascular invasion (2/8 vessels), RAS-mutant, no extrathyroidal extension, and no nodal involvement. Key discriminating findings: (1) presence of both capsular AND vascular invasion excludes NIFTP (option A requires NO invasion); (2) limited vascular invasion (≤4 foci) classifies this as minimally invasive follicular carcinoma; (3) absence of extrathyroidal extension and nodal disease indicates low-risk disease; (4) RAS mutation supports follicular-pattern carcinoma. The keyed answer D correctly classifies this as low-risk differentiated thyroid carcinoma and appropriately recommends TSH suppression without routine RAI, consistent with 2015 ATA guidelines that reserve RAI for intermediate/high-risk disease. Option A fails because invasion is present. Option B overstates risk by recommending routine RAI for minimally invasive disease. Option C misclassifies the histology (this is follicular carcinoma, not follicular variant PTC). Option E incorrectly labels limited angioinvasion as high-risk. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent, reflecting current risk stratification paradigms. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 3.8-cm encapsulated follicular-patterned thyroid lesion with capsular invasion and focal vascular invasion (2/8 vessels), RAS-mutant, no extrathyroidal extension, and no nodal involvement. Key discriminating findings: (1) presence of both capsular AND vascular invasion excludes NIFTP (option A requires NO invasion); (2) limited vascular invasion (≤4 foci) classifies this as minimally invasive follicular carcinoma; (3) absence of extrathyroidal extension and nodal disease indicates low-risk disease; (4) RAS mutation supports follicular-pattern carcinoma. The keyed answer D correctly classifies this as low-risk differentiated thyroid carcinoma and appropriately recommends TSH suppression without routine RAI, consistent with 2015 ATA guidelines that reserve RAI for intermediate/high-risk disease. Option A fails because invasion is present. Option B overstates risk by recommending routine RAI for minimally invasive disease. Option C misclassifies the histology (this is follicular carcinoma, not follicular variant PTC). Option E incorrectly labels limited angioinvasion as high-risk. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent, reflecting current risk stratification paradigms. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-017", "question": "A 66-year-old man with long-standing diabetes and peripheral neuropathy presents with chronic mesenteric ischemia symptoms and weight loss. CTA shows high-grade stenoses of both the celiac and superior mesenteric arteries (SMA) with a patent inferior mesenteric artery and extensive collateralization. There is a focal 2.5-cm jejunal stricture with mild upstream dilation but no mass. Intraoperatively, the bowel is patchy but viable; the stricture is firm and fibrotic. Biopsy shows transmural fibrosis without active vasculitis. Which strategy best addresses both symptoms and long-term gut viability?", "options": ["Endovascular stenting of SMA only, leaving celiac stenosis untreated", "Open antegrade aorto-SMA bypass plus segmental resection of the jejunal stricture", "Isolated resection of the jejunal stricture without mesenteric revascularization", "Retrograde iliac-to-SMA bypass only, with no bowel resection to avoid short-bowel risk", "Endovascular stenting of both celiac and SMA followed by observation of the stricture"], "answer": "B", "answer_index": 1, "explanation": "Symptomatic chronic mesenteric ischemia with structural fibrotic jejunal stricture requires both durable inflow restoration and removal of the fixed lesion; open aorto-SMA bypass offers superior long-term patency in multivessel disease, and resection treats the fibrotic stricture. SMA-only stenting (A) or dual-vessel stenting (E) may have higher restenosis and do not resolve fixed fibrosis. Resection alone (C) ignores global ischemia. Retrograde iliac-SMA bypass without resection (D) leaves a mechanical obstruction.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes a 66-year-old man with symptomatic chronic mesenteric ischemia (CMI) evidenced by high-grade stenoses of both celiac and SMA, plus a fixed fibrotic jejunal stricture causing mechanical obstruction. Key discriminating findings: (1) multivessel mesenteric disease requiring durable revascularization, (2) structural fibrotic stricture that cannot resolve with reperfusion alone, (3) viable bowel permitting safe resection. The keyed answer (B) correctly addresses both pathologies: open aorto-SMA bypass provides superior long-term patency compared to endovascular approaches in multivessel CMI, and segmental resection removes the fixed mechanical obstruction. Alternative analysis: (A) leaves celiac untreated and ignores stricture; (C) ignores global ischemia; (D) uses inferior retrograde conduit and leaves obstruction; (E) endovascular has higher restenosis rates in multivessel disease and observation won't resolve transmural fibrosis. Medical accuracy: The item correctly reflects that open bypass offers better durability than stenting for multivessel CMI, and that transmural fibrotic strictures require resection. No logical flaws; stem provides sufficient detail to discriminate. Minimal fix: None needed; item is valid and accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 66-year-old man with symptomatic chronic mesenteric ischemia (CMI) evidenced by high-grade stenoses of both celiac and SMA, plus a fixed fibrotic jejunal stricture causing mechanical obstruction. Key discriminating findings: (1) multivessel mesenteric disease requiring durable revascularization, (2) structural fibrotic stricture that cannot resolve with reperfusion alone, (3) viable bowel permitting safe resection. The keyed answer (B) correctly addresses both pathologies: open aorto-SMA bypass provides superior long-term patency compared to endovascular approaches in multivessel CMI, and segmental resection removes the fixed mechanical obstruction. Alternative analysis: (A) leaves celiac untreated and ignores stricture; (C) ignores global ischemia; (D) uses inferior retrograde conduit and leaves obstruction; (E) endovascular has higher restenosis rates in multivessel disease and observation won't resolve transmural fibrosis. Medical accuracy: The item correctly reflects that open bypass offers better durability than stenting for multivessel CMI, and that transmural fibrotic strictures require resection. No logical flaws; stem provides sufficient detail to discriminate. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-018", "question": "A 52-year-old woman with a history of Roux-en-Y gastric bypass 8 years ago presents with refractory iron-deficiency anemia and vague postprandial epigastric pain. EGD and colonoscopy are negative. Capsule endoscopy shows a circumferential, friable lesion in the excluded stomach. CT enterography confirms a 3.5-cm mass in the excluded gastric remnant without metastatic disease. Which surgical approach is most appropriate for oncologic control and access limitations?", "options": ["Laparoscopic transgastric gastroscopy through the gastric pouch with submucosal dissection of the lesion", "Laparoscopic-assisted resection of the excluded stomach mass via gastrotomy in the remnant and wedge resection", "Conversion of the Roux-en-Y gastric bypass to normal anatomy followed by subtotal gastrectomy", "Open completion gastrectomy including the excluded stomach with Roux-en-Y esophagojejunostomy", "Endoscopic ultrasound-guided radiofrequency ablation of the mass via transluminal puncture from the alimentary limb"], "answer": "D", "answer_index": 3, "explanation": "A 3.5-cm circumferential, friable mass in the excluded stomach is highly suspicious for carcinoma; completion gastrectomy provides oncologic resection with appropriate lymphadenectomy, best achieved via open approach given altered anatomy and access. Laparoscopic wedge resection (B) is inadequate for circumferential malignancy. Converting anatomy first (C) adds complexity without oncologic benefit. Transgastric endoscopic resection (A) and RFA (E) are inappropriate for likely invasive carcinoma in an excluded segment.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 52-year-old woman 8 years post-Roux-en-Y gastric bypass presenting with a 3.5-cm circumferential, friable mass in the excluded gastric remnant. Key discriminating findings include: (1) circumferential lesion suggesting extensive involvement, (2) friable appearance highly suspicious for malignancy, (3) size 3.5 cm indicating substantial tumor burden, (4) location in excluded stomach creating access challenges, (5) no metastatic disease on CT. The clinical problem is selecting appropriate surgical management for presumed gastric cancer in an excluded remnant. Option D (open completion gastrectomy with Roux-en-Y esophagojejunostomy) is the oncologically sound choice, providing adequate resection margins, lymphadenectomy, and reconstruction despite altered anatomy. Option A (transgastric submucosal dissection) is inadequate for invasive cancer. Option B (wedge resection) cannot address circumferential disease. Option C (anatomic conversion then gastrectomy) adds unnecessary complexity and operative risk. Option E (RFA) is inappropriate for likely invasive malignancy requiring formal resection. The item is medically accurate, reflecting standard oncologic principles for gastric cancer in post-bariatric anatomy. No logical flaws or missing critical details prevent unique best-answer selection. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 52-year-old woman 8 years post-Roux-en-Y gastric bypass presenting with a 3.5-cm circumferential, friable mass in the excluded gastric remnant. Key discriminating findings include: (1) circumferential lesion suggesting extensive involvement, (2) friable appearance highly suspicious for malignancy, (3) size 3.5 cm indicating substantial tumor burden, (4) location in excluded stomach creating access challenges, (5) no metastatic disease on CT. The clinical problem is selecting appropriate surgical management for presumed gastric cancer in an excluded remnant. Option D (open completion gastrectomy with Roux-en-Y esophagojejunostomy) is the oncologically sound choice, providing adequate resection margins, lymphadenectomy, and reconstruction despite altered anatomy. Option A (transgastric submucosal dissection) is inadequate for invasive cancer. Option B (wedge resection) cannot address circumferential disease. Option C (anatomic conversion then gastrectomy) adds unnecessary complexity and operative risk. Option E (RFA) is inappropriate for likely invasive malignancy requiring formal resection. The item is medically accurate, reflecting standard oncologic principles for gastric cancer in post-bariatric anatomy. No logical flaws or missing critical details prevent unique best-answer selection. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-019", "question": "A 45-year-old man with newly diagnosed mantle cell lymphoma receives R-CHOP followed by high-dose cytarabine. Six months later, he presents with worsening fatigue. CBC shows Hb 7.5 g/dL, MCV 105 fL, WBC 2,000/µL, platelets 40,000/µL. Bone marrow biopsy shows 18% myeloblasts with multilineage dysplasia and complex cytogenetics including monosomy 7. Flow cytometry is consistent with therapy-related myelodysplastic syndrome evolving toward AML. He has an HCT-CI score of 4 and a matched unrelated donor. Which management approach offers the best chance of long-term survival?", "options": ["Continue R-CHOP for mantle cell lymphoma and start azacitidine for t-MDS", "High-intensity induction chemotherapy with 7+3 followed by allogeneic stem cell transplantation in first remission", "Azacitidine plus venetoclax for cytoreduction, then allogeneic stem cell transplantation when feasible", "Supportive care only with transfusions and growth factors due to high transplant risk", "Immediate reduced-intensity allogeneic transplantation without further cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "Therapy-related MDS/AML with complex karyotype has poor prognosis; hypomethylating agent plus venetoclax can achieve remissions with better tolerability than intensive 7+3 in a comorbid patient, allowing subsequent allogeneic transplant for potential cure. Continuing lymphoma chemo (A) ignores aggressive secondary myeloid disease. High-intensity induction (B) risks excess toxicity given HCT-CI 4. Supportive care alone (D) is palliative. Immediate RIC transplant without cytoreduction (E) in 18% blasts is associated with high relapse and graft failure rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes therapy-related MDS with 18% blasts (approaching AML threshold of 20%), complex cytogenetics including monosomy 7, and an HCT-CI score of 4 indicating significant comorbidities. Key discriminating findings: (1) t-MDS/AML with poor-risk cytogenetics requiring definitive therapy, (2) HCT-CI 4 suggesting high toxicity risk with intensive chemotherapy, (3) matched unrelated donor available for transplant, (4) blast count 18% requiring cytoreduction before transplant. Option C (azacitidine+venetoclax followed by allogeneic transplant) is the current standard approach for older/comorbid patients with AML/high-risk MDS, offering better tolerability than 7+3 while achieving remissions that enable transplant. Option A ignores the aggressive myeloid malignancy. Option B (7+3) carries excessive toxicity risk given comorbidities. Option D is inappropriately palliative for a transplant-eligible patient. Option E (immediate transplant at 18% blasts without cytoreduction) risks high relapse and graft failure rates. The item accurately reflects modern AML/MDS management guidelines emphasizing risk-adapted therapy. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes therapy-related MDS with 18% blasts (approaching AML threshold of 20%), complex cytogenetics including monosomy 7, and an HCT-CI score of 4 indicating significant comorbidities. Key discriminating findings: (1) t-MDS/AML with poor-risk cytogenetics requiring definitive therapy, (2) HCT-CI 4 suggesting high toxicity risk with intensive chemotherapy, (3) matched unrelated donor available for transplant, (4) blast count 18% requiring cytoreduction before transplant. Option C (azacitidine+venetoclax followed by allogeneic transplant) is the current standard approach for older/comorbid patients with AML/high-risk MDS, offering better tolerability than 7+3 while achieving remissions that enable transplant. Option A ignores the aggressive myeloid malignancy. Option B (7+3) carries excessive toxicity risk given comorbidities. Option D is inappropriately palliative for a transplant-eligible patient. Option E (immediate transplant at 18% blasts without cytoreduction) risks high relapse and graft failure rates. The item accurately reflects modern AML/MDS management guidelines emphasizing risk-adapted therapy. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-020", "question": "A 32-year-old man with long-standing severe atopic dermatitis refractory to topical steroids and cyclosporine is started on dupilumab (anti-IL-4Rα). After 5 months, his skin disease improves markedly, but he develops new-onset peripheral eosinophilia (AEC 3,000/µL), adult-onset asthma, and transient pulmonary infiltrates on CT. ANCA is negative, and biopsy of a skin nodule shows eosinophil-rich vasculitis of small vessels. Which immunologic mechanism best explains this paradoxical adverse event?", "options": ["Unopposed IL-5-mediated eosinophil proliferation due to blockade of IL-4/IL-13 signaling", "Expansion of Th17 cells with increased IL-17 production driven by IL-4 pathway inhibition", "Emergence of autoreactive B cells secondary to impaired regulatory T-cell differentiation", "Type I interferon upregulation resulting from altered JAK-STAT signaling downstream of IL-4Rα", "Loss of IL-31 signaling leading to compensatory mast cell activation and eosinophilia"], "answer": "A", "answer_index": 0, "explanation": "Dupilumab blocks IL-4/IL-13 signaling, which can shift the Th2 cytokine milieu and lead to relative dominance of IL-5-driven eosinophil proliferation and activation, precipitating eosinophilic vasculitis/EGPA-like syndromes in susceptible patients. Th17 expansion (B), autoreactive B cells via Treg failure (C), interferon upregulation (D), or IL-31/mast cell effects (E) do not directly account for marked eosinophilia and small-vessel eosinophilic vasculitis associated with IL-4Rα blockade.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a classic dupilumab-associated paradoxical eosinophilic syndrome resembling EGPA (eosinophilic granulomatosis with polyangiitis). Key discriminating findings include: (1) dupilumab therapy for atopic dermatitis, (2) marked peripheral eosinophilia (AEC 3,000/µL), (3) new-onset asthma, (4) transient pulmonary infiltrates, (5) eosinophil-rich small-vessel vasculitis on biopsy, and (6) negative ANCA. These findings point to an eosinophil-driven process unmasked by IL-4/IL-13 blockade. Option A correctly identifies the mechanism: dupilumab blocks IL-4Rα, reducing IL-4/IL-13 signaling that normally suppresses IL-5 activity; this allows unopposed IL-5-mediated eosinophil proliferation and activation, precipitating EGPA-like syndromes. This is a recognized adverse event in dupilumab literature. Options B-E propose mechanisms unsupported by the clinical picture: Th17 expansion (B) doesn't explain eosinophilia; autoreactive B cells (C) lack evidence; type I interferon (D) is unrelated to this pathway; IL-31/mast cells (E) don't drive eosinophilic vasculitis. No logical flaws exist; the stem provides sufficient detail for unique best-answer selection. Medical accuracy is high, reflecting current understanding of dupilumab's immunologic effects. Minimal fix: none needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic dupilumab-associated paradoxical eosinophilic syndrome resembling EGPA (eosinophilic granulomatosis with polyangiitis). Key discriminating findings include: (1) dupilumab therapy for atopic dermatitis, (2) marked peripheral eosinophilia (AEC 3,000/µL), (3) new-onset asthma, (4) transient pulmonary infiltrates, (5) eosinophil-rich small-vessel vasculitis on biopsy, and (6) negative ANCA. These findings point to an eosinophil-driven process unmasked by IL-4/IL-13 blockade. Option A correctly identifies the mechanism: dupilumab blocks IL-4Rα, reducing IL-4/IL-13 signaling that normally suppresses IL-5 activity; this allows unopposed IL-5-mediated eosinophil proliferation and activation, precipitating EGPA-like syndromes. This is a recognized adverse event in dupilumab literature. Options B-E propose mechanisms unsupported by the clinical picture: Th17 expansion (B) doesn't explain eosinophilia; autoreactive B cells (C) lack evidence; type I interferon (D) is unrelated to this pathway; IL-31/mast cells (E) don't drive eosinophilic vasculitis. No logical flaws exist; the stem provides sufficient detail for unique best-answer selection. Medical accuracy is high, reflecting current understanding of dupilumab's immunologic effects. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]